| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/09/2003 | CA2451959A1 Nucleic acid participating in the formation of presenilin-2-gene exon 5-defective splicing variant |
| 01/09/2003 | CA2451955A1 Antibodies to opgl |
| 01/09/2003 | CA2451850A1 Medicinal compositions |
| 01/09/2003 | CA2451840A1 Fused pyrimidine dhfr inhibitors as antibacterials |
| 01/09/2003 | CA2451800A1 Fused pyrimidines as d-alanyl-d-alanine ligase inhibitors |
| 01/09/2003 | CA2451795A1 Cell-based high-throughput screening methods |
| 01/09/2003 | CA2451755A1 Pyridazinone |
| 01/09/2003 | CA2451739A1 Hcv e1e2 vaccine compositions |
| 01/09/2003 | CA2451728A1 Zonisamide use in headache |
| 01/09/2003 | CA2451699A1 Compositions and methods for inhibiting platelet activation and thrombosis |
| 01/09/2003 | CA2451579A1 Use of corrinoids for application in skin diseases |
| 01/09/2003 | CA2451464A1 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 01/09/2003 | CA2451324A1 Physiological tissue repair and functional organ regeneration by cultivation of regenerative stem cells in vivo and in situ |
| 01/09/2003 | CA2451228A1 Novel heteroaryl derivatives, their preparation and use |
| 01/09/2003 | CA2451195A1 Antitumoral formulations of thioxanthenone |
| 01/09/2003 | CA2451129A1 Glaucoma treatments with reduced hyperpigmentation |
| 01/09/2003 | CA2451128A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | CA2451125A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | CA2451039A1 Methods for preparation and use of 1.alpha.,24(s)-dihydroxyvitamin d2 |
| 01/09/2003 | CA2451037A1 Method of treating malignancy associated hypercalcemia using active vitamin d analogues |
| 01/09/2003 | CA2450982A1 New derivatives of oxazolidinones as antibacterial agents |
| 01/09/2003 | CA2450722A1 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | CA2450686A1 Substituted 8-arylquinoline pde4 inhibitors |
| 01/09/2003 | CA2450356A1 Bone anabolic compounds and methods of use |
| 01/09/2003 | CA2450354A1 Enhanced systemic absorption of intradermally delivered substances |
| 01/09/2003 | CA2449486A1 Methods of using soluble epoxide hydrolase inhibitors |
| 01/09/2003 | CA2447280A1 Use of sulodexide for the treatment of inflammatory bowel disease |
| 01/09/2003 | CA2424645A1 New use of dipeptidyl peptidase iv inhibitors |
| 01/09/2003 | CA2420548A1 Composition comprising vitamin c and a pyrone or furanone compound |
| 01/09/2003 | CA2418543A1 New dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents |
| 01/08/2003 | EP1273590A2 Estra- 1,3,5(10)-triene Derivatives, Methods of Preparing Such Compounds and Pharmaceutical Compositions Containing Them |
| 01/08/2003 | EP1273587A1 Process for the preparation of a 3-vinylcephem compound |
| 01/08/2003 | EP1273582A1 Heterocyclo-alkylsulfonyl pyrazoles as anti-inflammatory/analgesic agents |
| 01/08/2003 | EP1273581A1 New process for the preparation of the trihydrate of the magnesium salt of S-omeprazole |
| 01/08/2003 | EP1273580A1 Sulfonyl heteroaryl triazoles as anti-inflammatory and analgesic agents |
| 01/08/2003 | EP1273578A1 Benzopyran derivatives and antiallergic agent containing the same |
| 01/08/2003 | EP1273576A1 Sulfonyl aryl triazoles as anti-inflammatory/analgesic agents |
| 01/08/2003 | EP1273575A1 Diazepane derivatives or salts thereof |
| 01/08/2003 | EP1273571A1 Nitrogenous compounds and antiviral drugs containing the same |
| 01/08/2003 | EP1273308A1 Peptide-flavonoid conjugates, their preparation and use in uv protection |
| 01/08/2003 | EP1273307A1 Preparations for preventing bile acid diarrhea |
| 01/08/2003 | EP1273305A1 Medical preparation for inhalation comprising Antithrombin for treating inflammatory lung diseases and ARDS |
| 01/08/2003 | EP1273301A2 Pharmaceutical preparations based on active ingredients susceptible to illicit administration |
| 01/08/2003 | EP1273300A2 A stable external preparation containing aspirin |
| 01/08/2003 | EP1273299A1 Minoxidil-containing preparations |
| 01/08/2003 | EP1273298A2 Ritonavir in combination with an additional HIV protease inhibitor for treating aids |
| 01/08/2003 | EP1273297A1 Vitamin E for the treatment of diseases in which the binding of the transcription factor NF-KB and/or AP-1 to promoter target sites has a beneficial effect (eg AIDS, cardiac infarction) |
| 01/08/2003 | EP1273296A2 Combination chemotherapy |
| 01/08/2003 | EP1273295A1 Composition comprising ozonized oils and/or other ozonized natural and/or synthetic products and their use in pharmaceutical, cosmetic, dietetic or food supplement compositions in human and veterinary medicine |
| 01/08/2003 | EP1273294A1 Fenofibrate pharmaceutical composition with a higher bioavailability and its manufacturing process |
| 01/08/2003 | EP1273293A1 Fenofibrate suspension in a hydrophilic polymer solution |
| 01/08/2003 | EP1273292A1 Optimised formulation of tobramycin for aerosolization |
| 01/08/2003 | EP1273291A1 Brittle-coating, soft core dosage form |
| 01/08/2003 | EP1273289A1 Pharmaceutical compositions containing ascomycin derivatives |
| 01/08/2003 | EP1273288A1 Pharmaceutical compositions containing rapamycin derivatives |
| 01/08/2003 | EP1273287A1 Oily compositions containing highly fat-soluble drugs |
| 01/08/2003 | EP1273284A2 High SPF nontacky/nongreasy UV-photoprotecting compositions comprising particulates of MMA crosspolymers |
| 01/08/2003 | EP1272907A2 Compliance tracking method |
| 01/08/2003 | EP1272853A2 Methods for identifying and using amyloid-inhibitory compounds |
| 01/08/2003 | EP1272670A2 Diagnosis of diseases associated with dna adducts |
| 01/08/2003 | EP1272666A1 A functional assay of high-density lipoprotein |
| 01/08/2003 | EP1272665A1 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
| 01/08/2003 | EP1272663A2 Polymorphisms in the human cyp2b6 gene and their use in diagnostic and therapeutic applications |
| 01/08/2003 | EP1272653A2 Methods for ansamitocin production |
| 01/08/2003 | EP1272646A2 Regulation of human serine racemase enzyme |
| 01/08/2003 | EP1272636A2 A gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| 01/08/2003 | EP1272635A1 Cryptic-like secreted protein |
| 01/08/2003 | EP1272634A1 Human ion channel protein and polynucleotides encoding the same |
| 01/08/2003 | EP1272614A1 Differentiation of bone marrow cells into neuronal cells and uses therefor |
| 01/08/2003 | EP1272610A1 Mutant bank |
| 01/08/2003 | EP1272528A1 Chitosan and method of preparing chitosan |
| 01/08/2003 | EP1272514A1 Dna encoding human vanilloid receptor vr3 |
| 01/08/2003 | EP1272506A1 Human aminoacyl-trna synthetase polypeptides useful for the regulation of angiogenesis |
| 01/08/2003 | EP1272505A1 8beta-substituted-11beta-pentyl- and 11beta-hexyl-estra-1,3,5(10)-triene derivatives |
| 01/08/2003 | EP1272504A1 8beta-hydrocarbyl-substituted estratrienes for use as selective estrogens |
| 01/08/2003 | EP1272499A1 Pharmaceutical compositions containing oligosaccharides and preparation thereof |
| 01/08/2003 | EP1272490A2 Sodium salt of an azo derivative of 5-aminosalicylic acid |
| 01/08/2003 | EP1272489A1 Process for preparing crystalline form i of cabergoline |
| 01/08/2003 | EP1272488A2 Tri-aryl-substituted-ethane pde4 inhibitors |
| 01/08/2003 | EP1272487A1 Bicyclic heteroaryl compounds as inhibitors of the interaction between the integrin alpha4beta1 receptor and vcam-1 and/or fibronectin |
| 01/08/2003 | EP1272485A1 Novel 1,2,3,4-tetrahydrosioquinoline, their preparation method and their use as fungicides |
| 01/08/2003 | EP1272484A2 Benzoamide piperidine compounds as substance p antagonists |
| 01/08/2003 | EP1272481A1 4-fluoroalkyl-2h-benzopyrans with anti-estrogenic activity |
| 01/08/2003 | EP1272479A2 Novel compounds for enhancing chemotherapy |
| 01/08/2003 | EP1272477A1 Pyrimidine compounds |
| 01/08/2003 | EP1272471A1 Non-steroidal, tetracyclic compounds for estrogen-related treatments |
| 01/08/2003 | EP1272470A1 Amorphous torasemide modification |
| 01/08/2003 | EP1272469A1 Naphthalene derivatives and their pharmaceutical use |
| 01/08/2003 | EP1272468A1 Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands |
| 01/08/2003 | EP1272467A1 Cathepsin cysteine protease inhibitors |
| 01/08/2003 | EP1272465A2 Compounds and methods to increase plasma hdl cholesterol levels and improve hdl functionality |
| 01/08/2003 | EP1272459A1 7- and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline compounds |
| 01/08/2003 | EP1272457A2 Compounds for modulating cell proliferation |
| 01/08/2003 | EP1272456A1 Hydrazide and alkoxyamide angiogenesis inhibitors |
| 01/08/2003 | EP1272455A1 Halogenated 2-amino-4, 5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
| 01/08/2003 | EP1272230A1 An injectable bone mineral substitute material |
| 01/08/2003 | EP1272225A2 Lipid-based systems for targeting diagnostic agents |
| 01/08/2003 | EP1272223A1 Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same |
| 01/08/2003 | EP1272222A2 Compositions for drug delivery |
| 01/08/2003 | EP1272221A2 Peptide conjugates for drug delivery |